163 related articles for article (PubMed ID: 10930966)
1. Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy.
Canaparo R; Casale F; Muntoni E; Zara GP; Della Pepa C; Berno E; Pons N; Fornari G; Eandi M
Br J Clin Pharmacol; 2000 Aug; 50(2):146-53. PubMed ID: 10930966
[TBL] [Abstract][Full Text] [Related]
2. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
3. An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia.
Pivot X; Guardiola E; Etienne M; Thyss A; Foa C; Otto J; Schneider M; Magné N; Bensadoun RJ; Renée N; Milano G
Eur J Cancer; 2000 May; 36(7):852-7. PubMed ID: 10785589
[TBL] [Abstract][Full Text] [Related]
4. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
[TBL] [Abstract][Full Text] [Related]
5. Serum erythropoietin levels in ovarian cancer patients receiving chemotherapy.
Pedain C; Herrero J; Künzel W
Eur J Obstet Gynecol Reprod Biol; 2001 Oct; 98(2):224-30. PubMed ID: 11574136
[TBL] [Abstract][Full Text] [Related]
6. Toxicity of platinum compounds.
Hartmann JT; Lipp HP
Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
[TBL] [Abstract][Full Text] [Related]
7. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
[TBL] [Abstract][Full Text] [Related]
8. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
[TBL] [Abstract][Full Text] [Related]
9. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.
Forastiere AA; Metch B; Schuller DE; Ensley JF; Hutchins LF; Triozzi P; Kish JA; McClure S; VonFeldt E; Williamson SK
J Clin Oncol; 1992 Aug; 10(8):1245-51. PubMed ID: 1634913
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies.
Perez RP; Chen E; Thaddeus Beck J; Shirai K; Neil Hayes D; Shen T; Baldwin JR; Bryant KB; He S; Chin S
Pharmacol Res Perspect; 2019 Dec; 7(6):e00519. PubMed ID: 31788317
[TBL] [Abstract][Full Text] [Related]
12. 5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Vokes EE; Moormeier JA; Ratain MJ; Egorin MJ; Haraf DJ; Mick R; Weichselbaum RR
Cancer Chemother Pharmacol; 1992; 29(3):178-84. PubMed ID: 1733549
[TBL] [Abstract][Full Text] [Related]
13. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.
Go RS; Adjei AA
J Clin Oncol; 1999 Jan; 17(1):409-22. PubMed ID: 10458260
[TBL] [Abstract][Full Text] [Related]
14. A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
Forastiere AA; Natale RB; Takasugi BJ; Goren MP; Vogel WC; Kudla-Hatch V
J Clin Oncol; 1987 Feb; 5(2):190-6. PubMed ID: 3543242
[TBL] [Abstract][Full Text] [Related]
15. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin. The better platinum in head and neck cancer?
Volling P; Schröder M; Rauschning W; Achterrath W; Stennert E
Arch Otolaryngol Head Neck Surg; 1989 Jun; 115(6):695-8. PubMed ID: 2655667
[TBL] [Abstract][Full Text] [Related]
17. Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Vermorken JB; Mesia R; Rivera F; Remenar E; Kawecki A; Rottey S; Erfan J; Zabolotnyy D; Kienzer HR; Cupissol D; Peyrade F; Benasso M; Vynnychenko I; De Raucourt D; Bokemeyer C; Schueler A; Amellal N; Hitt R
N Engl J Med; 2008 Sep; 359(11):1116-27. PubMed ID: 18784101
[TBL] [Abstract][Full Text] [Related]
18. Serum immunoerythropoietin levels in patients with cancer receiving cisplatin-based chemotherapy.
Smith DH; Goldwasser E; Vokes EE
Cancer; 1991 Sep; 68(5):1101-5. PubMed ID: 1655216
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey.
Burgy M; Barthélémy P; Lefevre F; Dupret-Bories A; Truntzer P; Korenbaum C; Flesch H; Bronner G; Borel C
Oncology; 2017; 93(1):11-17. PubMed ID: 28423384
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic study in carboplatin, cisplatin and 5-fluorouracil regimen for advanced oesophageal cancer.
Leger-Enreille A; Cure H; Pezet D; Bargnoux PJ
Anticancer Res; 1994; 14(6A):2327-9. PubMed ID: 7825967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]